Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma Handan Kaya Email author Teresa Ragazzini Erkin Aribal Ýlter Güney Esin Kotilođlu Article Received: 09 November 2001 Accepted: 20 November 2001 DOI :
10.1007/BF03032384
Cite this article as: Kaya, H., Ragazzini, T., Aribal, E. et al. Pathol. Oncol. Res. (2001) 7: 279. doi:10.1007/BF03032384 Abstract Genomic amplification and oncoprotein overexpression of Her-2/neu was studied on ultrasound core needle biopsy specimens of the infiltrative ductal carcinomas of the breast. We performed “two colour” fluorescence in situ hybridization (FISH) for Her-2/neu and chromosome 17 and compared the FISH results with the immunohistochemical overexpression of Her-2/neu protein by 2 antibodies (DAKO HercepTest and the BioGenex monoclonal antibody AM 134-5M). Furthermore, following radical mastectomy with axillary dissection, Her-2/neu status of the patients were compared with the well known histopathological prognostic factors such as histologic grade, tumor stage, lympho/ vascular invasion, surgical margin status and Paget’s disease. Amplification was demonstrated 27% of the cases. Her-2/neu protein overexpression was detected in 47% and 80% of the cases with CB11 and HercepTest respectively. We revealed statistically significant association between the tumor, oncoprotein expression and oncogene amplification (p<0.05). The results of our study showed that combination of IHC and FISH methods enhances the evaluation of tumor genetics at both gene and protein level for the analysis of Her-2/neu in breast carcinoma.
Keywords breast carcinoma FISH immunohistochemistry Her-2/neu
References 1.2
Pettine S, Place R, Babu S, et al : Stereotactic breast biopsy accurate, minimally invasive, and cost effective. Am J Surg 171:474–476, 1996.
PubMed CrossRef Google Scholar 2.2
Wallace JE, Sayler C, McDowell NG, et al : The role of stereotactic biopsy assessment of nonpalpable breast lesions. Am J Surg 172:471–473, 1996.
CrossRef Google Scholar 3.2
Timothy WJ, Kalliopi PS, Prioleau JE, et al : Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor. Mod Pathol 11:259–264, 1998.
Google Scholar 4.2
Bargmann CI, Hung MC, Weinberg RA : The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226–230, 1986.
PubMed CrossRef Google Scholar 5.2
Slamon DJ, Clark GM, Wong SG, et al : Human breast cancer: correlation of relapse and survival with amplification of the
HER-2/neu oncogene. Science 235:177–182, 1987.
PubMed CrossRef Google Scholar 6.2
Evans AJ, Pider SE, Ellis IO, et al : Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team: Clin Radiol 49:559–562, 1994.
PubMed Google Scholar 7.2
Pauletti G, Godolphin W, Press MF, et al : Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63–72, 1996.
PubMed Google Scholar 8.2
Bankfalvi A, Simon R, Brandt B, et al : Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathol 37:411–419, 2000.
CrossRef Google Scholar 9.2
Jimenez RE, Wallis T, Tabasczka P, et al : Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13:37–45, 2000.
PubMed CrossRef Google Scholar 10.2
Press MF, Bernstein L, Thomas PA, et al : HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894–2904, 1997.
PubMed Google Scholar 11.2
Persons DL, Borelli KA, Hsu PH : Quantitation of HER-2/
neu and c-myc gene amplification in breast carcinoma using fluo-rescence in situ hybridization. Mod Pathol 10:720–727, 1997.
PubMed Google Scholar 12.2
Hoang MP, Sahin AA, Ordonez NG, et al : Her-2/
neu gene amplification compared with Her-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113:852–859, 2000.
PubMed CrossRef Google Scholar 13.2
Ratcliffe N, Wells W, Wheeler K, et al : The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal appearing breast epithelium. Mod Pathol 10:1247–1252, 1997.
PubMed Google Scholar 14.2
Scorilas A, Yotis J, Strvolemos K, et al : c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res 15:1543–1648, 1995.
PubMed Google Scholar 15.2
An H-X, Niederacher D, Dominik SI, et al : Int-2 and c-erbB-2 gene amplification detected in 70 frozen human breast carcinomas by quantitative polymerase chain reaction. Anticancer Res 17:3133–3136, 1997.
PubMed Google Scholar 16.2
Slamon DJ, Godolphin W, Jones LA, et al : Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712, 1989.
PubMed CrossRef Google Scholar 17.2
Hopman AHN, Ramaekers FCS, Raap AK, et al : In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochem 89:307–316, 1988.
CrossRef Google Scholar 18.2
De Potter CR, Schelfout AM : The neu-protein and breast cancer. Virchows Arch 426:107–115, 1995.
PubMed CrossRef Google Scholar 19.2
Ross JS, Fletcher JA : The HER-2/
neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413–428, 1998.
PubMed CrossRef Google Scholar 20.2
Press MF, Hung G, Godolphin W, et al : Sensitivity of HER-2/neu antibodies in archival tissue samples potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771–2777, 1994.
PubMed Google Scholar 21.2
Tubbs RR, Pettay JD, Roche PC, et al : Discrepancies in clinical laboratory testing of eligibility for transtuzumab therapy: apparent immunohistochemical false positives do not get the message. J Clin Oncol 15:2714–2721, 2001.
Google Scholar © Arányi Lajos Foundation 2001
Authors and Affiliations Handan Kaya Email author Teresa Ragazzini Erkin Aribal Ýlter Güney Esin Kotilođlu 1. Department of Pathology Marmara University Hospital Istanbul Turkey 2. Department of Oncology University of Bologna Italy 3. Department of Radiology Marmara University Hospital Istanbul 4. Department of Medical Biology Marmara University Hospital Istanbul